The company’s website looked credible. It explained that the business was developing a treatment for a metabolic disease. The science was presented carefully, the problem appeared significant, and the opportunity seemed worthy of attention. The investor deck covered the familiar ground too: the condition, the treatment approach, the market and the company’s progress.
Nothing in the material looked careless. Yet the business felt smaller on the page than it did in conversation.
That became clear only after I spoke with the founder a few times.
As he explained how the disease was currently understood, how patients moved through the treatment system and where existing approaches fell short, another commercial opportunity began to take shape. It was large enough to change the way the company should have been viewed.
The website barely acknowledged it. The deck did not name it clearly.
Some of the relevant information was present, although it appeared in fragments. A person with enough domain knowledge might have connected the points and recognised the implication. Everyone else was being asked to notice a market that the company itself had not explicitly described.
The opportunity had always been inside the business. It was missing from the story being told about it.
Accurate information can still produce an incomplete picture
Scientific and technical businesses tend to be careful about claims. That caution is understandable. A biopharma company cannot afford to use language that runs ahead of the evidence. Its communication has to respect the stage of development, the limits of the science and the scrutiny that comes from investors, regulators, partners and medical experts.
The problem begins when restraint turns into under-explanation. The company may describe the disease correctly. It may explain the treatment mechanism and show credible data. Each section can remain factually sound while the larger commercial meaning remains difficult to see. This is a wider organisational problem: valuable work and evidence can remain underappreciated until someone connects them into a coherent account.
That was the issue here.
The communication told the reader what the company was working on. It did not make clear how wide the opportunity could become when the treatment was viewed against the full market structure.
Accuracy had been achieved. Understanding had been left to the audience.
Founders often carry the complete argument in their heads
The founder had spent years thinking about the disease area. He understood the science, the patient need, the limitations of current options and the way the market was divided. He could move between these subjects quickly because the connections had become familiar to him.
During a conversation, he could explain why one group of patients was especially relevant, how that group related to the treatment being developed and why the commercial potential extended beyond the segment highlighted in the existing material.
For him, these ideas were connected. For someone reading the website, they were not.
This is a recurring problem in founder-led businesses, especially those built around specialised knowledge. The founder has lived inside the opportunity for so long that some of its most important implications begin to feel obvious.
They may mention one fact in a product section, another in a market slide and a third during a meeting. Because they know how the pieces fit, they assume an informed reader will see the same picture.
That assumption is risky. An investor, partner or senior candidate sees only what the business places in front of them. They do not know which connection they are expected to make. They may not even realise that an important part of the commercial case is absent.
The website described the treatment. The founder explained the opportunity.
A treatment description and an opportunity narrative perform different jobs.
The treatment description explains what the company is developing. It may cover the scientific approach, the intended use, the stage of development and the problem being addressed.
The opportunity narrative shows why the work matters at the level of the business.
It connects the treatment to the real experience of patients, the limitations of available options, the structure of the market and the change that could follow if the company succeeds.
In this case, the existing material contained enough information to suggest that the company was working on an important problem. The founder’s explanation showed that the business might be addressing a wider and more valuable market than the communication indicated.
That difference matters.
A reader could walk away from the website thinking, “This is an interesting treatment for a defined disease segment.”
After speaking with the founder, the conclusion became more substantial: “This company may have access to an additional market that materially changes the scale of the opportunity.”
The science had not changed during the conversation. The context had.
An important submarket had been left between the lines
The missing opportunity was not an unrelated market added to make the pitch sound larger. It arose from the company’s existing science, the treatment context and the way the disease affected a wider group.
The details had remained implicit.
There may have been a sentence on the website that pointed towards it. A chart in the deck may have contained a number that supported it. Another slide may have described a patient group without establishing its commercial significance.
The reader received the ingredients. The company never stated what they added up to.
This distinction deserves attention because technical businesses often confuse the presence of information with the communication of meaning.
A deck can include every relevant fact and still fail to make the central case. The audience should not have to assemble the investment thesis independently.
When a submarket is large enough to influence how the business is valued, it cannot be treated as a footnote or left for a specialist reader to discover.
It needs a defined place in the narrative.
Sophisticated audiences should not be expected to infer everything
Founders sometimes believe that spelling out the implication will make the material sound promotional. They assume investors and strategic partners will prefer a restrained presentation and draw their own conclusions.
Sophisticated audiences do appreciate discipline. They also appreciate clarity.
A serious investor will test the claim, examine the assumptions and challenge the market model. That process works better when the company has stated the argument clearly.
Leaving the argument incomplete does not make the business appear more rigorous. It may simply cause the reader to evaluate the company against a narrower opportunity.
The same issue affects partnerships.
A larger pharmaceutical company may understand the treatment and still miss how it could fit a wider strategic priority. A potential collaborator may view the business as relevant to one limited area because the company has not explained the adjacent opportunity.
Even senior candidates can be affected. People often join early-stage science companies because they believe in the scale of the problem and the possibility of meaningful impact. When the story understates the opportunity, the company may struggle to attract people who would have found the full ambition compelling.
Under-explaining can change how the business is valued
Market perception is shaped by the story an audience can actually understand.
A biopharma venture may possess strong science, credible leadership and a promising treatment. If its communication presents the business as operating within one narrow segment, external stakeholders may assess it through that smaller lens.
That can influence the questions they ask.
The investor may focus on whether the first market alone is large enough. The partner may see limited strategic relevance. The reader may wonder whether the company has sufficient room to grow after the initial indication.
A clearly articulated submarket changes the discussion. It does not guarantee investment or commercial success. It gives the audience a more accurate basis for evaluating what the company could become.
This is why strategic narrative belongs close to business strategy. The work is not confined to improving language. It affects which opportunity the market believes the company is pursuing.
The founder conversation became a form of discovery
The larger opportunity emerged through repeated conversation rather than a single interview. The first discussion helped establish the science and the company’s immediate plans. Later conversations moved into the patient groups, treatment pathways and market assumptions that sat behind the formal material.
The submarket became visible because the founder was able to explain how those elements related.
This is one reason a standard content questionnaire often fails in complex businesses.
Questions such as “What are your key differentiators?” or “Who is your target audience?” usually produce compressed answers. They gather information, though they may miss the reasoning that gives the information commercial weight.
The more useful conversation explores what the founder sees that other people may be overlooking.
Which part of the disease burden receives too little attention? Where does the current market definition become restrictive? Which patient group is poorly served? What changes when the treatment is considered beyond its most obvious initial use?
These questions draw out the founder’s judgement rather than collecting copy points.
The narrative begins to take shape when someone listens for the connection that the founder considers obvious and the outside world has never been shown.
Extraction alone is not enough
Founder knowledge rarely arrives in finished communication form. During a conversation, the founder may move between science, patient behaviour, commercial potential and future development plans. They may use technical shorthand or assume familiarity with concepts that require explanation.
The raw material can be powerful and difficult to follow. It has to be structured without flattening it.
In scientific businesses, this requires care. Simplifying too aggressively can weaken credibility. Preserving every technical detail can bury the implication.
The work involves deciding what each audience needs to understand and in what order.
A website visitor may need a clear view of the unmet need and the company’s larger purpose. An investor deck must connect the scientific case to the commercial opportunity. A potential partner may require more detail about strategic fit and development pathways.
The level of detail changes. The core account should remain consistent.
The market opportunity needed to become explicit
Once the additional submarket had been identified, it could no longer remain scattered across the communication. The website needed to name the wider opportunity in language that a serious reader could understand. The investor deck needed to show where the submarket sat within the company’s commercial thesis and why the science was relevant to it. Once that direction was settled, writers, designers and specialist agencies could receive a strategic brief grounded in the actual opportunity.
The argument also needed evidence.
A larger opportunity should not be presented through an inflated market figure or an ambitious line on a slide. The company had to establish the patient population, treatment context and connection to its approach with enough discipline to withstand scrutiny.
That balance is essential.
The aim is to help the audience see the full opportunity while remaining honest about the company’s current stage and the work still ahead.
When done well, this makes the story more compelling because it becomes more complete, rather than more promotional.
One narrative can guide several business conversations
The value of articulating the opportunity extends beyond the website and deck. A clear market narrative can shape partnership discussions, recruitment, investor outreach and founder communication. It gives each audience an appropriate entry point into the same business understanding.
The founder no longer has to wait for a long meeting to reveal why the opportunity is larger than it appears.
The website can introduce the idea. The deck can develop the commercial case. A founder article can explain why the submarket has been overlooked. Partnership material can show how it relates to the strategic priorities of another company.
Each asset performs a different role. Together, they make the opportunity easier to recognise.
This is how founder knowledge becomes reusable.
The founder should remain the source of insight
Translating founder expertise into company communication does not mean removing the founder from the narrative. Their understanding gives the story its authority.
They know why the opportunity matters because they have studied the problem, made scientific choices and built the company around a particular view of the disease. That perspective cannot be replaced by generic market research.
Their role, however, should not be limited to explaining the whole business from the beginning in every private meeting.
Marketing leadership can capture the founder’s thinking, test the logic, structure the argument and carry it across communication. Writers, designers and specialist agencies can then adapt it into different formats.
The founder remains involved where their contribution has the greatest value: interpretation, judgement and strategic insight.
The organisation takes responsibility for making those insights accessible.
A business can be larger than its communication
Before my conversations with the founder, the company looked like a credible biopharma venture working on an important metabolic disease.
After those conversations, it looked like a business with access to a substantially wider market opportunity.
Nothing new had been added to the company during that time. The treatment remained the same. The underlying science remained the same. The submarket had already existed.
The difference lay in whether the pieces had been connected clearly enough for an outsider to see them.
Many founder-led and technically complex businesses carry more commercial potential than their external communication reveals. Their websites describe the work. Their decks present data. Their founders hold the conclusion in their heads.
The market can only evaluate the opportunity it has been helped to understand.
When an important submarket is real, relevant and supported by evidence, leaving it implicit is not restraint. It is an incomplete account of the business.